Accéder au contenu
Merck

Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production.

Clinical and experimental pharmacology & physiology (2017-08-31)
Shuguang Han, Jing Xu, Xiangjun Guo, Mao Huang
RÉSUMÉ

Curcumin, an active phenolic agent extract from the Curcuma longa, exhibits excellent anti-cancer, anti-inflammation, and neuroprotective effects. We aimed to investigate the anti-influenza role of curcumin in vitro and in vivo. The effect of curcumin on replication of influenza A virus (IAV) was examined in human lung cancer cell line A549, as well as in a mouse model. Curcumin could inhibit IAV in vitro and alleviate the severity of the disease in the mouse after infection with IAV. The results also indicated that curcumin could trigger expression of Heme oxygenase-1 in vivo and attenuate IAV-induced injury to the lung tissue. Furthermore, curcumin could regulate immune response following IAV infection through inhibiting production of local inflammatory cytokines. In addition, curcumin was found to inhibit NF-κB signalling in macrophages, as well as the subsequent production of cytokines/chemokines responding to IAV infection, by enhancing IκBα and AMPK. Our current study supports the potential of curcumin as a promising treatment against IAV infection, whose effect may be mediated by regulating immune response to prevent injury to the lung tissue.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-grippe A, de type nucléoprotéine, mélange des clones A1 et A3, ascites fluid, Chemicon®, from mouse